A Platform Designed for High-Impact Cancers
The initial focus is on breast and pancreatic tumours, where early detection and rapid intervention can make the greatest difference. These cancers are among the most difficult and costly to treat using current methods.
By enabling faster, safer, and more effective intervention, ScanNanoTreat has the potential to significantly improve patient outcomes and reduce the clinical and economic burden associated with these diseases.
A Foundation for Europe’s Future Theranostics Market
ScanNanoTreat’s concept is not just scientifically ambitious—it is economically transformative. The system is designed to position Europe as a leader in the fast-growing theranostics market, aiming to capture 10–17% of a €493 million market by 2032, representing €35–60 million in potential annual revenue by 2035.
These projections demonstrate both the commercial attractiveness of the platform and its alignment with Europe’s strategic priorities in medical technology.
A Radical Step Forward
ScanNanoTreat embodies a powerful idea: that cancer treatment should be faster, safer, more precise, and more patient-centred. By merging cutting-edge photonics, nanotechnology, and medical imaging, it opens the door to a new generation of integrated oncology solutions.
Eric Le Roux / Université Claude Bernard Lyon 1
From Concept to Reality
Over the next three years, ScanNanoTreat will advance the system from TRL 3 to TRL 5, complete preclinical work, refine the integrated imaging-therapy workflow, and develop a full regulatory and business plan. This will prepare the technology for clinical trials and the launch of a dedicated spin-off to bring the solution to market.
Photo : Eric Le Roux / Université Claude Bernard Lyon 1